Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

4 big deal reports: Enbridge shells out $14B for Dominion utilities

Published 09/10/2023, 03:26 PM
Updated 09/10/2023, 03:26 PM
© Reuters.

By Davit Kirakosyan

Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this past week: deals at Enbridge and Dominion Energy, WestRock and Smurfit Kappa, NextGen Healthcare and Thoma Bravo, and potential sale of Alteryx.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Enbridge to pay $14 billion to Dominion Energy for 3 utilities

Enbridge (NYSE:ENB) agreed to acquire EOG, Questar, and PSNC from Dominion Energy (NYSE:D) at a combined value of $14 billion, which includes $9.4B cash and $4.6B of assumed debt, as reported in real time on InvestingPro.

The acquisitions will expand Enbridge's presence in the US utility sector, adding gas utility operations in Ohio, North Carolina, Utah, Idaho, and Wyoming. Post-acquisition, Enbridge’s gas utility business will become the largest in North America.

Following the announcement, Enbridge shares fell more than 5% in Wednesday's session.

WestRock and Smurfit Kappa confirm merger deal

Smurfit Kappa Group and WestRock (NYSE:WRK) confirmed reports of discussions about a possible merger to form "Smurfit WestRock." The new company would be incorporated and domiciled in Dublin, Ireland, with the Americas operations in Atlanta, Georgia.

Post-merger, Smurfit WestRock's ordinary shares will be listed on the NYSE, with a subsequent aim to seek US equity index inclusion. Smurfit Kappa's existing premium listing on the London Stock Exchange might be replaced by a standard listing, and a delisting from Euronext Dublin is also in the cards.

Credit Suisse said the proposed deal "would have significant strategic and operational merits."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

InvestingPro

Truist sees $44/share as potential acquisition price for Alteryx

Truist Securities reiterated its Buy rating and $40.00 price target on Alteryx (NYSE:AYX), following reports that the company is working with Qatalyst Partners to explore a potential sale.

According to the firm, Alteryx possesses valuable core technology assets in the self-service data preparation space. With the current industry focus on making data and analytics more accessible through AI, the firm believes that Alteryx's technology could remain relevant whether it continues as an independent entity or merges with another company in the evolving IT landscape.

According to Truist, any acquisition could happen at a valuation that implies a share price of about $44.

Shares closed the week with more than an 18% gain.

NextGen Healthcare to be taken private by Thoma Bravo

Nextgen Healthcare (NASDAQ:NXGN) agreed to be acquired by Thoma Bravo for $23.95 per share in cash. The transaction is anticipated to close in Q4/23, subject to customary closing conditions, including approval by NextGen Healthcare shareholders and required regulatory approvals.

Following the completion of this deal, NextGen Healthcare will transition into a privately held company.

NextGen shares closed the week with more than a 22% gain.

InvestingPro | Anticipate Market Trends With Breaking News

Latest comments

The gig economy is changing the nature of work.
Economic indicators suggest moderate growth.
noman
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.